EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

A novel technology-driven enzyme replacement therapy for Pompe disease

Naresh K Meena, Kylie Gray, Jonathan Roberts, Michael DiGruccio, Vaughn Weaver, Lin Liu, Hung Do, R Russell Gotschall, Nina Raben

Molecular Therapy Advances · 2026-12 · 34 (4) · 201867

DOI: 10.1016/j.omta.2026.201867 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Therapy Advances, 2026-12. Verfasst von Naresh K Meena und 8 weiteren Autor:innen. Beteiligte Einrichtung: Glyko Consulting LLC, Oklahoma City, OK, USA. Die Arbeit nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pompe disease, a prototypical lysosomal storage disorder (LSD), is caused by a deficiency of glycogen-degrading lysosomal enzyme acid alpha-glucosidase (GAA). Enzyme replacement therapy (ERT) options for Pompe disease have recently expanded to include avalglucosidase alfa and cipaglucosidase alfa/miglustat. These new recombinant enzymes (rhGAAs) were designed to overcome the limitations of alglucosidase alfa, the first-generation ERT. Both rhGAAs have a higher content of bis-phosphorylated mannose-6-phosphate (bis-M6P) N-glycans for more efficient muscle targeting via the cation-independent mannose 6-phosphate receptor. Despite the initial positive response, new ERTs offer only incremental advances, and some patients continue to decline. Here, we used a novel technology to co-express rhGAA with engineered GlcNAc-1-phosphotransferase to produce a new compound, M021, with exceptionally high levels of natural bis-M6P glycans. In this large preclinical study, we demonstrate that M021 outperforms avalglucosidase and cipaglucosidase-evaluated here as a standalone rhGAA component-in removing accumulated glycogen and ameliorating autophagy-lysosomal pathway dysfunction. Importantly, monthly dosing rather than standard biweekly treatment following debulking sustained low levels of glycogen and autophagic markers. Furthermore, initiating a monthly regimen from the start of therapy resulted in similarly low glycogen levels. The bis-M6P enrichment platform offers a strategy with therapeutic potential across the spectrum of LSDs.

Schlagwörter

Stichwörter der Autor:innen

Pompe diseaseautophagyenzyme replacement therapylysosomal storage diseasesmuscle

Autor:innen und Institutionen

  • Glyko Consulting LLC, Oklahoma City, OK, USA.
  • Sentio Biosciences, Maryland Heights, MO, USA.
  • Sable Analytics, Fort Seybert, WV, USA.
  • M6P Therapeutics, Saint Louis, MO, USA.
  • M6P Therapeutics (Switzerland) GmbH, Schaffhausen, Switzerland.

Zitieren

APA

Meena, N. K., Gray, K., Roberts, J., DiGruccio, M., Weaver, V., Liu, L., Do, H., Gotschall, R. R., & Raben, N. (2026). A novel technology-driven enzyme replacement therapy for Pompe disease. Molecular Therapy Advances, 34(4), 201867. https://doi.org/10.1016/j.omta.2026.201867

Vancouver

Meena NK, Gray K, Roberts J, DiGruccio M, Weaver V, Liu L, et al. A novel technology-driven enzyme replacement therapy for Pompe disease. Molecular Therapy Advances. 2026;34(4):201867. doi:10.1016/j.omta.2026.201867

BibTeX
@article{Meena2026,
  author = {Meena, Naresh K and Gray, Kylie and Roberts, Jonathan and DiGruccio, Michael and Weaver, Vaughn and Liu, Lin and Do, Hung and Gotschall, R Russell and Raben, Nina},
  title = {A novel technology-driven enzyme replacement therapy for Pompe disease},
  journal = {Molecular Therapy Advances},
  year = {2026},
  volume = {34},
  number = {4},
  pages = {201867},
  doi = {10.1016/j.omta.2026.201867}
}
Kostenlos starten →